期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 63, 期 11, 页码 -出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.00959-19
关键词
rifamycins; periprosthetic joint infection; Staphylococcus aureus; Staphylococcus epidermidis; biofilm; rifampin; rifabutin; rifapentine; rifaximin; rpoB
资金
- National Institute of Allergy and Infectious Diseases of the National Institutes of Health [R21AI125870]
The in vitro activities of rifampin, rifabutin, rifapentine, and rifaximin were tested against 200 periprosthetic joint infection (PJI)-associated staphylococci. Seven rifampin-resistant isolates had MICs of >= 4 mu g/ml. Three isolates had rifampin MICs of 0.25 to 1 mu g/ml and harbored an Asp471Gly RpoB variant, suggesting that the CLSI rifampin-susceptible staphylococcal breakpoint of <= 1 mu g/ml may be too high. The remaining isolates had rifampin MICs of <= 0.016 mu g/ml, and the rifampin, rifabutin, rifapentine, and rifaximin minimum biofilm bactericidal concentrations (MBBC) for >= 50% of isolates were 8, 1, 2, and 4 mu g/ml (for S. aureus) and 2, 0.06, 0.25, and 0.5 mu g/ml (for S. epidermidis), respectively, for rifampin-susceptible isolates. Nonrifampin rifamycins have promising staphylococcal activity, including antibiofilm activity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据